Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq:APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the abstract titled “ATRN-W1051, a novel and potent WEE1 inhibitor for the treatment of CCNE1-overexpressing ovarian cancer” will be presented at the 14th Biennial Virtual Ovarian Cancer Research Seminar Series presented by the Rivkin Center and the American Association for Cancer Research (AACR). The series will take place on September 21, 22, 28, and 29, 2022, with each day scheduled to run from 12:00-2:00pm U.S. Pacific Time.
Related news for (APRE)
- Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
- Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
- Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
- Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics